A Placebo Controlled, Single Blind, Randomised Study Investigating the Safety, Tolerability and Pharmacokinetics of Repeated Oral Doses of GSK598809 in Healthy Male and Female Volunteers for 28 Days.
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2017
At a glance
- Drugs GSK 598809 (Primary)
- Indications Smoking withdrawal
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 27 Oct 2008 Actual start date changed from Feb 2007 to Mar 2007 as reported by ClinicalTrials.gov.
- 27 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.